SLC40A1 in iron metabolism, ferroptosis, and disease: A review

被引：9
作者：
Zhang, Yan [1 ]
Zou, Liyi [2 ]
Li, Xiaodan [3 ]
Guo, Long [1 ]
Hu, Baoguang [4 ]
Ye, Hua [1 ,5 ]
Liu, Yi [1 ,5 ]
机构：
[1] Guangdong Med Univ, Sch Pharm, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Guangdong, Peoples R China
[2] Guangdong Med Univ, Sch Pharm, Guangdong Key Lab Res & Dev Nat Drugs, Dongguan, Peoples R China
[3] Peoples Hosp Longhua Dist, Shenzhen, Guangdong, Peoples R China
[4] Binzhou Med Univ Hosp, Dept Gastrointestinal Surg, Binzhou, Shandong, Peoples R China
[5] Guangdong Med Univ, Sch Pharm, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang 524023, Guangdong, Peoples R China
来源：
WIRES MECHANISMS OF DISEASE | 2024年 / 16卷 / 04期
关键词：
disease; ferroptosis; iron metabolism; SERUM FERRITIN; HEPCIDIN EXPRESSION; INSULIN-RESISTANCE; CELL-DEATH; CANCER; INFLAMMATION; TRANSPORTER; FERROPORTIN; BINDING; ANEMIA;
D O I：
10.1002/wsbm.1644
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Solute carrier family 40 member 1 (SLC40A1) plays an essential role in transporting iron from intracellular to extracellular environments. When SLC40A1 expression is abnormal, cellular iron metabolism becomes dysregulated, resulting in an overload of intracellular iron, which induces cell ferroptosis. Numerous studies have confirmed that ferroptosis is closely associated with the development of many diseases. Here, we review recent findings on SLC40A1 in ferroptosis and its association with various diseases, intending to explore new directions for research on disease pathogenesis and new therapeutic targets for prevention and treatment. This article is categorized under: Cancer > Genetics/Genomics/Epigenetics Metabolic Diseases > Molecular and Cellular Physiology
引用
收藏
页数：13
相关论文
共 88 条
[1]   A novel mammalian iron-regulated protein involved in intracellular iron metabolism [J].
Abboud, S ;
Haile, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) :19906-19912
[2]   Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma [J].
Adachi, Makiko ;
Kai, Keita ;
Yamaji, Koutaro ;
Ide, Takao ;
Noshiro, Hirokazu ;
Kawaguchi, Atsushi ;
Aishima, Shinichi .
HISTOPATHOLOGY, 2019, 75 (01) :63-73
[3]   Anemia of inflammation: the cytokine-hepcidin link [J].
Andrews, NC .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (09) :1251-1253
[4]   Obesity and Diabetes [J].
Aras, Mohini ;
Tchang, Beverly G. ;
Pape, Joy .
NURSING CLINICS OF NORTH AMERICA, 2021, 56 (04) :527-541
[5]   Serum hepcidin concentrations and type 2 diabetes [J].
Aregbesola, Alex ;
Voutilainen, Sari ;
Virtanen, Jyrki K. ;
Aregbesola, Adeola ;
Tuomainen, Tomi-Pekka .
WORLD JOURNAL OF DIABETES, 2015, 6 (07) :978-982
[6]   Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin [J].
Aschemeyer, Sharraya ;
Qiao, Bo ;
Stefanova, Deborah ;
Valore, Erika V. ;
Sek, Albert C. ;
Ruwe, T. Alex ;
Vieth, Kyle R. ;
Jung, Grace ;
Casu, Carla ;
Rivella, Stefano ;
Jormakka, Mika ;
Mackenzie, Bryan ;
Ganz, Tomas ;
Nemeth, Elizabeta .
BLOOD, 2018, 131 (08) :899-910
[7]   Ferroptosis and Necroptosis in the Kidney [J].
Belavgeni, Alexia ;
Meyer, Claudia ;
Stumpf, Julian ;
Hugo, Christian ;
Linkermann, Andreas .
CELL CHEMICAL BIOLOGY, 2020, 27 (04) :448-462
[8]   Remodeling phenotype of human subcutaneous adipose tissue macrophages [J].
Bourlier, V. ;
Zakaroff-Girard, A. ;
Miranville, A. ;
De Barros, S. ;
Maumus, M. ;
Sengenes, C. ;
Galitzky, J. ;
Lafontan, M. ;
Karpe, F. ;
Frayn, K. N. ;
Bouloumie, A. .
CIRCULATION, 2008, 117 (06) :806-815
[9]   Haemochromatosis [J].
Brissot, Pierre ;
Pietrangelo, Antonello ;
Adams, Paul C. ;
de Graaff, Barbara ;
McLaren, Christine E. ;
Loreal, Olivier .
NATURE REVIEWS DISEASE PRIMERS, 2018, 4
[10]   Anemias [J].
Broadway-Duren, Jacqueline B. ;
Klaassen, Hillary .
CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2013, 25 (04) :411-+
123456789